Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to determine the maximum tolerated dose (MTD) of
OratecanTM. Eligible subjects of this study are patients with histologically or cytologically
confirmed malignant solid tumor refractory to standard therapy or for which no established
therapy exists at the time of study participation.